Bicocca Open Archive

Logo unimib boa
ALBERTI, PAOLA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 13.020
EU - Europa 7.126
AS - Asia 4.406
SA - Sud America 305
AF - Africa 46
OC - Oceania 30
Continente sconosciuto - Info sul continente non disponibili 15
Totale 24.948
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.806
SG - Singapore 1.913
IT - Italia 1.791
DE - Germania 1.272
CN - Cina 1.150
SE - Svezia 931
IE - Irlanda 881
RU - Federazione Russa 724
HK - Hong Kong 578
UA - Ucraina 343
GB - Regno Unito 333
BR - Brasile 253
CA - Canada 190
FI - Finlandia 175
VN - Vietnam 133
IN - India 132
AT - Austria 130
FR - Francia 121
DK - Danimarca 119
ID - Indonesia 111
TR - Turchia 109
JP - Giappone 94
NL - Olanda 76
BE - Belgio 50
KR - Corea 48
ES - Italia 47
AU - Australia 28
PK - Pakistan 18
CH - Svizzera 16
TW - Taiwan 16
IR - Iran 15
AR - Argentina 14
EU - Europa 13
PL - Polonia 12
RO - Romania 12
BG - Bulgaria 11
GR - Grecia 11
IL - Israele 11
MX - Messico 11
BD - Bangladesh 10
EG - Egitto 10
HR - Croazia 9
IQ - Iraq 9
PT - Portogallo 9
UZ - Uzbekistan 9
CZ - Repubblica Ceca 8
ZA - Sudafrica 8
CL - Cile 7
LV - Lettonia 7
NO - Norvegia 7
PE - Perù 7
EC - Ecuador 6
GT - Guatemala 6
KZ - Kazakistan 6
NG - Nigeria 6
PH - Filippine 6
SI - Slovenia 6
AL - Albania 5
CO - Colombia 5
MA - Marocco 5
SA - Arabia Saudita 5
SC - Seychelles 5
TH - Thailandia 5
VE - Venezuela 5
AZ - Azerbaigian 4
BH - Bahrain 4
HU - Ungheria 4
LU - Lussemburgo 4
MY - Malesia 4
AE - Emirati Arabi Uniti 3
AO - Angola 3
BO - Bolivia 3
JM - Giamaica 3
MD - Moldavia 3
PA - Panama 3
PY - Paraguay 3
RS - Serbia 3
BN - Brunei Darussalam 2
ET - Etiopia 2
IS - Islanda 2
JO - Giordania 2
KG - Kirghizistan 2
LT - Lituania 2
NZ - Nuova Zelanda 2
TN - Tunisia 2
UG - Uganda 2
UY - Uruguay 2
A1 - Anonimo 1
A2 - ???statistics.table.value.countryCode.A2??? 1
AM - Armenia 1
BF - Burkina Faso 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
GE - Georgia 1
KE - Kenya 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
LI - Liechtenstein 1
MM - Myanmar 1
Totale 24.946
Salva come PNG Salva come JPEG
Città #
Ann Arbor 3.158
Singapore 1.311
Fairfield 860
Dublin 855
Woodbridge 831
Wilmington 790
Chandler 718
Frankfurt am Main 683
Milan 656
Ashburn 601
Hong Kong 571
Houston 533
Dearborn 505
Santa Clara 429
Seattle 369
New York 367
Jacksonville 364
Princeton 330
Cambridge 290
Nanjing 207
Shanghai 142
Boardman 131
Guangzhou 118
Vienna 112
Munich 109
Jakarta 108
Lawrence 94
Beijing 92
Helsinki 92
Altamura 77
Dong Ket 69
Chicago 60
Los Angeles 60
Rome 59
Lachine 55
Nanchang 55
San Diego 53
Andover 52
Shenyang 51
Toronto 49
Carate Brianza 45
Council Bluffs 40
Hebei 40
Brussels 38
Hangzhou 38
Nuremberg 38
Tianjin 38
London 37
Pune 35
Tokyo 35
Ottawa 34
Jinan 33
Mountain View 32
Melzo 31
Changsha 29
Kunming 28
Norwalk 28
Falls Church 25
Edmonton 24
Florence 22
São Paulo 22
Zhengzhou 22
Mainz 21
Shangdi 21
Fremont 20
Jiaxing 19
Washington 19
Dallas 18
Lissone 18
Lappeenranta 17
Sacramento 16
Romola 15
Turin 15
Athens 14
Bologna 14
Ningbo 14
Sesto San Giovanni 14
Yuseong-gu 14
Paris 13
Chongqing 12
Hefei 12
Kiev 12
Amsterdam 11
Baltimore 11
Brescia 11
Salt Lake City 11
Shenzhen 11
Bari 10
Bergamo 10
Hyderabad 10
Kocaeli 10
Monza 10
Naples 10
Cagliari 9
Canazei 9
Chengdu 9
Como 9
Manchester 9
Sydney 9
Trieste 9
Totale 17.276
Salva come PNG Salva come JPEG
Nome #
Nelarabine-Induced Neurotoxicity: Reversible Damage not only on Peripheral Nerves 372
Translational Approach to Oxaliplatin Induced Peripheral Neurotoxicity - Neurophysiology: the Link between Bed and Bench "side" 350
Peripheral neuropathy induced by microtubule-targeted chemotherapies: Insights into acute injury and long-term recovery 333
Evaluation of the Profile and Mechanism of Neurotoxicity of Water-Soluble [Cu(P)4]PF6 and [Au(P)4]PF6 (P = thp or PTA) Anticancer Complexes 315
Neurophysiological, nerve imaging and other techniques to assess chemotherapy-induced peripheral neurotoxicity in the clinical and research settings 310
High-dose intravenous immunoglobulins reduce nerve macrophage infiltration and the severity of bortezomib-induced peripheral neurotoxicity in rats 309
Chemotherapy-induced peripheral neurotoxicity in the era of pharmacogenomics 298
Evaluation of the psychometric properties of the EORTC chemotherapy-induced peripheral neuropathy questionnaire (QLQ-CIPN20) 257
Role of Organic Transporters 1 and 2 in Cisplatin mediated neurotoxicity 246
Risk stratification of oxaliplatin induced peripheral neurotoxicity applying electrophysiological testing of dorsal sural nerve 241
Patients' and physicians' interpretation of chemotherapy-induced peripheral neurotoxicity 235
Neurofilament light chain: a specific serum biomarker of axonal damage severity in rat models of Chemotherapy-Induced Peripheral Neurotoxicity 233
Guillain-Barré syndrome related to COVID-19 infection 231
Pathogenic role of delta 2 tubulin in bortezomib-induced peripheral neuropathy 225
The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings 223
Rasch-built Overall Disability Scale for patients with chemotherapy-induced peripheral neuropathy (CIPN-R-ODS) 223
Topiramate prevents oxaliplatin-related axonal hyperexcitability and oxaliplatin induced peripheral neurotoxicity 223
Genetic determinants of chronic oxaliplatin-induced peripheral neurotoxicity: A genome-wide study replication and meta-analysis 221
Human Intravenous Immunoglobulin Alleviates Neuropathic Symptoms in a Rat Model of Paclitaxel-Induced Peripheral Neurotoxicity 220
Molsidomine reduces the severity of Vincristine-induced peripheral neurotoxicity in rats 214
Neuronopathies and polyneuropathies: a ready to use translational neurophysiological protocol in rodent models 208
Neurofilament light chain as disease biomarker in a rodent model of chemotherapy induced peripheral neuropathy 204
Psychometric Testing of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire–Chemotherapy-Induced Peripheral Neuropathy 20-Item Scale Using Pooled Chemotherapy-Induced Peripheral Neuropathy Outcome Measures Standardization and Alliance for Clinical Trials in Oncology A151408 Study Data 203
The validation of neuroactive drug selection based on combinatorial screening in bortezomib-induced neurotoxicity models. 203
Ion Channel and Transporter Involvement in Chemotherapy-Induced Peripheral Neurotoxicity 194
Incidence of atypical acute nerve hyperexcitability symptoms in oxaliplatin-treated patients with colorectal cancer 191
Neuropathic pain and chemotherapy-induced peripheral neurotoxicity: the issue 190
Nerve Excitability Testing to Unravel Chemotherapy Induced Peripheral Neurotoxicity (CIPN) Pathogenesis: Altered Axonal Excitability as a Possible Pivotal Event Related to Platinum Compounds and Taxanes 189
Assessment of oxaliplatin-induced peripheral neurotoxicity with different treatment schedules 189
Study of perpheral neurotoxicity of different doses of oxaliplatin in cd1 mice 188
Chemotherapy-Induced Peripheral Neurotoxicity assessment: a critical revision of the currently available tools 187
Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients 186
Correspondence between neurophysiological and clinical measurements of chemotherapy-induced peripheral neuropathy: secondary analysis of data from the CI-PeriNoms study 184
Sensory-motor paclitaxel polyneuropathy characterization in a rat model 180
Advanced age and liability to oxaliplatin-induced peripheral neuropathy: post hoc analysis of a prospective study 178
Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin 177
Molsidomide provides neuroprotection against vincristine-induced peripheral neurotoxicity 177
Toxic Medications in Charcot-Marie-Tooth Patients: A Systematic Review 176
Chemotherapy-induced neuropathy 172
Severe, reversible nelarabine-induced neuropathy and myelopathy 172
A Longitudinal Study on Oxaliplatin Induced Peripheral Neuropathy – Incidence and Facts About the “Real Life” Population And Actual Dose 169
Topiramate possible double efficacy profile: Oxaliplatin-induced peripheral neurotoxicity prevention and anticancer synergic action 168
Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity: Results from a prospective multicenter study 166
Neuroprotectant agents against oxaliplatin induced neurotoxicity: lackings, facts and future prospective 163
Efficacy of a Novel Sigma-1 Receptor Antagonist for Oxaliplatin-Induced Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase IIa Clinical Trial 163
An in vivo and in vitro neurophysiological approach to acute and chronic oxaliplatin-induced peripheral neurotoxicity 162
Chemotherapy induced peripheral neurotoxicity: Six essential articles for effective future research 161
Chemotherapy-induced Peripheral Neuropathy 159
MR309/E-52862, a first-in-class sigma-1 receptor antagonist, in oxaliplatin-induced peripheral neuropathy. An exploratory Phase II clinical trial 159
Animal Models for the Study of Human Central and Peripheral Nervous System Diseases 159
Dorsal sural nerve conduction study in the assessment of oxaliplatin induced peripheral neuropathy 157
ACCURATE NEUROPHYSIOLOGICAL MONITORING FOR SENSORY NEUROPATHY IN MOUSE MODELS OF CHEMOTHERAPY INDUCED PERIPHERAL NEUROTOXICITY 157
Incidence, characteristics, and associations of oxaliplatin-induced peripheral neuropathy in colorectal cancer patients: Results of a prospective, multicenter, international study. 157
Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal cancer patients 155
EVALUATION OF THE EFFICACY OF PERIPHAGEN NEUROTROPHIN-3 EXPRESSING VECTOR FOR OXALIPLATIN INDUCED PERIPHERAL NEUROPATHY. 153
Distal pain and carpal tunnel syndrome diagnosis among cashiers: a longitudinal study 153
Introduction to the Italian section for young neurologists 151
Chemotherapy-induced peripheral neurotoxicity can be misdiagnosed by the National Cancer Institute Common Toxicity scale 150
When progressive dysphagia could be related to an “old friend” – a case report 150
Long-term course of oxaliplatin-induced polyneuropathy: a prospective two-year follow-up study 150
Chemotherapy-induced peripheral neurotoxicity in cancer survivors: an underdiagnosed clinical entity? 150
Neurophysiological examination of dorsal sural nerve 149
Platinum-drugs Induced Peripheral Neurotoxicity: clinical course and preclinical evidence 149
NERVE EXCITABILITY TESTING IN ANIMAL MODELS OF OXALIPLATIN INDUCED PERIPHERAL NEUROTOXICITY: ION CHANNEL DYSFUNCTION AS A POSSIBLE PATHOGENETIC MECHANISM. 149
Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin 148
The significance of dorsal sural nerve recordings in early detecting oxaliplatin-induced peripheral neuropathy. 148
Chemotherapy-induced peripheral neurotoxicity–outcome measures: the issue 146
Intravenous Immunoglobulin Preparation Attenuates Pain Behaviors in a Wistar Rat Model of Bortezomib-Induced Peripheral Neuropathy 144
Chemotherapy Induced Peripheral Neurotoxicity (CIPN): neurological burden from a physician and patient point of view 143
Topiramate Prevents Oxaliplatin Neurotoxicity in a rat model 143
Morpho-Functional Characterisation of the Rat Ventral Caudal Nerve in a Model of Axonal Peripheral Neuropathy 142
ERIBULIN, PACLITAXEL, IXABEPILONE AND VINORELBINE-INDUCED PERIPHERAL NEUROPATHY IN MICE: INSIGHTS IN LONG-TERM RECOVERY 142
Overview and critical revision of clinical assessment tools in chemotherapy-induced peripheral neurotoxicity 142
NERVE EXCITABILITY TESTING AS THE LINK BETWEEN ANATOMY AND PHYSIOLOGY: AXONAL EXCITABILITY TESTING TO TEST IN VIVO MECHANISMS OF PERIPHERAL NERVE DAMAGE. 141
Morphology meets function to unravel Oxaliplatin Induced Peripheral Neurotoxicity (OIPN) 141
Guillain–Barré Syndrome Associated with COVID-19 140
Erratum to: Distal pain and carpal tunnel syndrome diagnosis among cashiers: a longitudinal study (Int Arch Occup Environ Health, 10.1007/s00420-017-1237-8) 138
Ivig Effect In A Wistar Rat Model Of Bortezomib-Induced Peripheral Neuropathy 138
Liability of the voltage-gated potassium channel KCNN3 repeat polymorphism to acute oxaliplatin-induced peripheral neurotoxicity 138
Neurofilament light chain serum levels as a possible paclitaxel-induced peripheral neurotoxicity biomarker: pilot and feasibility study. 137
Long-term recovery from chemotherapy-induced neuropathy following paclitaxel, ixabepilone, eribulin and vinorelbine in mice 136
Advanced neurophysiology - a translational approach to neuropathy and neuropathic pain 136
Addressing the Need of a Translational Approach in Peripheral Neuropathy Research: Morphology Meets Function 136
Chemotherapy induced peripheral neurotoxicity: the search for the ideal outcome measure 135
How to assess models of oxaliplatin induced peripheral neurotoxicity – a neurophysiological translational approach 134
Methods for in vivo studies in rodents of chemotherapy induced peripheral neuropathy 134
EMG Recordings at Rest to Verify Axonal Hyperexcitability in a Rat Model of Oxaliplatin Induced Peripheral Neurotoxicity 134
Topiramate in Oxaliplatin-Induced Peripheral Neurotoxicity: more than neuroprotection. 132
Major issue in chemotherapy-induced peripheral neuropathy (cipn): lack of standardized measurement scales. ciperinoms study: validity and reliability in cipn assessment 131
Tackling Oxaliplatin Induced Peripheral neurotoxicity: from bed to bench side and back. 131
Ghrelin agonist HM01 attenuates chemotherapy-induced neurotoxicity in rodent models 130
Responsiveness and Minimal Clinical Important Difference (MCID) of the Total Neuropathy Score clinical and nurse versions in CIPN 130
Management of Side Effects in the Personalized Medicine Era: Chemotherapy-Induced Peripheral Neuropathy 129
Blood neurofilament light chains as a potential damage marker in chemotherapy-induce peripheral neuropathy rodent models 127
Oxaliplatin induced peripheral neurotoxicity – a neurophysiological translational approach 126
The Content Validity of a Chemotherapy-Induced Peripheral Neuropathy Patient-Reported Outcome Measure 126
Macrophage infiltration in different preclinical models of chemotherapy-induced peripheral neurotoxicity 124
Sodium-Calcium Exchanger 2: A Pivotal Role in Oxaliplatin Induced Peripheral Neurotoxicity and Axonal Damage? 123
Morphofunctional characterisation of axonal damage in different rat models of chemotherapy-induced peripheral neurotoxicity: the role of nerve excitability testing 121
Clinical pattern and associations of oxaliplatin acute neurotoxicity: A prospective study in 170 patients with colorectal cancer 120
Totale 17.652
Salva come PNG Salva come JPEG
Categoria #
all - tutte 102.049
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 102.049
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020963 0 0 0 0 0 0 0 0 336 288 267 72
2020/20213.952 184 153 439 367 290 498 470 505 305 265 172 304
2021/20222.010 147 252 179 179 171 165 79 91 112 130 174 331
2022/20233.550 434 806 333 313 272 575 78 193 251 69 121 105
2023/20243.401 112 168 174 158 389 706 623 161 240 94 95 481
2024/20255.766 449 1.032 827 426 789 378 681 327 857 0 0 0
Totale 26.709